A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes
- Steven A. Safren, PhD1⇑,
- Jeffrey S. Gonzalez, PhD2,3,
- Deborah J. Wexler, MD4,
- Christina Psaros, PhD1,
- Linda M. Delahanty, MS4,
- Aaron J. Blashill, PhD1,
- Aleksandra I. Margolina, BA1 and
- Enrico Cagliero, MD4
- 1Behavioral Medicine Service, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- 2Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY
- 3Diabetes Research Center, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY
- 4MGH Diabetes Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- Corresponding author: Steven A. Safren, E-mail:
Objective To test cognitive behavioral therapy for adherence and depression (CBT-AD) in type-2 diabetes. We hypothesized that CBT-AD would improve adherence, depression, and, secondarily, hemoglobin A1c (A1C).
Research Design and Methods 87 adults with unipolar depression and uncontrolled type-2 diabetes received Enhanced Treatment As Usual (ETAU) including medication adherence-, self-monitoring of blood glucose (SMBG)-, and lifestyle-counseling; a provider letter documented psychiatric diagnoses. Those randomized to the intervention arm additionally received 9-11 sessions of CBT-AD.
Results Immediately after acute treatment (4-months), adjusting for baseline, CBT-AD had 20.7 percentage points greater oral medication adherence on electronic pill cap (95% CI: -31.14, -10.22, =.000); 30.2 percentage points greater SMBG adherence via glucometer downloads (95% CI: -42.95, -17.37, p=.000); 6.44 points lower depression scores on the Montgomery-Asberg Depression Rating Scale (95% CI: 2.33, 10.56, p=.002); .74 points lower on the Clinical Global Impression (95% CI: .16, 1.32, p=.01); and .72 units lower A1C (95% CI: .29, 1.15, p=.001) relative to ETAU. Analyses of 4-, 8- and 12-month follow-up time-points indicated that CBT-AD maintained 24.3 percentage points higher medication adherence (95% CI: -38.2, -10.3, p=.001); 16.9 percentage points greater SMBG adherence (95% CI: -33.3, -.5, p=.043); and .63 units lower A1C (95% CI: .06, 1.2, p=.03) after acute treatment ended. For depression, there was some evidence of continued improvement post-treatment, but no between-groups difference.
Conclusions CBT-AD is an effective intervention for adherence, depression, and glycemic control, with enduring and clinically meaningful benefits for diabetes self-management and glycemic control, in adults with type-2 diabetes and depression.
- Received April 5, 2013.
- Accepted October 20, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.